首页> 外文期刊>Surgical oncology >Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging.
【24h】

Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging.

机译:以pTNM分期为分层的高危人群滤泡性甲状腺癌的手术策略。

获取原文
获取原文并翻译 | 示例
           

摘要

This study determined cancer survival rates and follow-up status at different pTNM stages to stratify risk groups in follicular thyroid carcinoma. Two hundred and fourteen follicular thyroid cancer patients (167 females, 47 males) who underwent surgery and followed-up treatment at a single medical center were enrolled in this retrospective study. Tumors were staged by UICC-TNM criteria (6th edition). Low risk for follicular thyroid cancer was defined as pT1N0M0. (Moderate-risk group) was defined as all other patients in pTNM stage I, and high risk as patients in stages II-IV. After mean follow-up of 9.6+/-0.3 years, 1.6% (2/120), 21.9% (7/32), 5.6% (1/18) and 52.3% (23/44) of patients in pTNM stages I-IV, respectively, died of thyroid cancer. Of 214 follicular thyroid cancer patients, 35 (16.4%), 85 (39.7%) and 94 (43.9%) were defined as low-, moderate- and high-risk groups at the time of surgery. None of the low-risk patients died, and all achieved disease-free status. In the moderate- and high-risk groups, 2.4% (2/85) and 27.7% (26/94) died of thyroid cancer. The moderate- and high-risk groups underwent near-total thyroidectomy and (131)I therapies, and 15 of 107 (14.9%) died of thyroid cancer while 18 (16.8%) had persistent disease at the end of the study period. Multiple regression analysis demonstrated that tumor size, radioactive iodide therapy and post-operative thyroglobulin level significantly differ between the mortality and survival groups. In conclusion, the low-risk follicular thyroid cancer group as defined by pTNM staging had excellent prognosis. Total thyroidectomy and post-operative radioactive iodide therapy are mandatory in moderate- and high-risk groups. Over one-fourth of the follicular thyroid cancer patients in the high-risk group died of thyroid cancer despite aggressive treatment.
机译:这项研究确定了不同pTNM阶段的癌症存活率和随访状态,以对滤泡性甲状腺癌的危险人群进行分层。这项回顾性研究纳入了在单个医疗中心接受手术和随访治疗的214例甲状腺滤泡癌患者(女性167例,男性47例)。肿瘤按UICC-TNM标准分期(第6版)。滤泡性甲状腺癌的低风险定义为pT1N0M0。 (中度风险组)定义为pTNM I期的所有其他患者,高风险为II-IV期的患者。在平均随访9.6 +/- 0.3年后,pTNM I期患者分别为1.6%(2/120),21.9%(7/32),5.6%(1/18)和52.3%(23/44) -IV分别死于甲状腺癌。在214例甲状腺滤泡癌患者中,有35例(16.4%),85例(39.7%)和94例(43.9%)在手术时被定义为低,中,高风险组。低危患者均无死亡,均达到无病状态。在中高风险组中,有2.4%(2/85)和27.7%(26/94)死于甲状腺癌。在研究期末,中高危组接受了几乎完全的甲状腺切除术和(131)I治疗,其中107例中的15例(14.9%)死于甲状腺癌,而18例(16.8%)患有持续性疾病。多元回归分析表明,死亡率和生存组之间的肿瘤大小,放射性碘治疗和术后甲状腺球蛋白水平显着不同。总之,pTNM分期定义的低危甲状腺滤泡癌组预后良好。中高风险组必须进行全甲状腺切除术和术后放射性碘治疗。尽管采取了积极的治疗措施,高危组的滤泡性甲状腺癌患者中有超过四分之一死于甲状腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号